PDT Partners LLC Has $253,000 Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

PDT Partners LLC lowered its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 45.5% in the third quarter, HoldingsChannel reports. The fund owned 7,554 shares of the biotechnology company’s stock after selling 6,296 shares during the period. PDT Partners LLC’s holdings in AnaptysBio were worth $253,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Ensign Peak Advisors Inc boosted its position in AnaptysBio by 74.4% during the 2nd quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock worth $1,898,000 after acquiring an additional 32,313 shares during the last quarter. Victory Capital Management Inc. boosted its position in AnaptysBio by 677.9% during the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after acquiring an additional 206,750 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after acquiring an additional 168,813 shares during the last quarter. Alpha DNA Investment Management LLC acquired a new position in AnaptysBio during the 2nd quarter worth approximately $399,000. Finally, nVerses Capital LLC boosted its position in AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 1,400 shares during the last quarter.

AnaptysBio Trading Down 9.8 %

ANAB opened at $22.00 on Wednesday. AnaptysBio, Inc. has a 1-year low of $14.70 and a 1-year high of $41.31. The stock’s fifty day simple moving average is $27.65 and its 200 day simple moving average is $29.72. The stock has a market cap of $669.46 million, a PE ratio of -3.62 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. Equities analysts forecast that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

Insider Activity at AnaptysBio

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the transaction, the insider now directly owns 15,398 shares of the company’s stock, valued at $595,440.66. This represents a 8.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Eric J. Loumeau sold 8,720 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.82, for a total value of $347,230.40. Following the completion of the transaction, the insider now directly owns 7,020 shares in the company, valued at approximately $279,536.40. This represents a 55.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,440 shares of company stock worth $892,936. Company insiders own 33.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ANAB shares. JPMorgan Chase & Co. reduced their price target on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. Guggenheim upped their price objective on AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday. Wedbush reiterated an “outperform” rating and set a $42.00 price objective on shares of AnaptysBio in a research note on Thursday, November 14th. Finally, Truist Financial upped their price objective on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $54.64.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.